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Today, we are witnessing the deadliest pandemic of our time. As of May 25 2021, over 167 million people have been 
affected with the coronavirus disease 2019 (COVID-19) globally with approximately 3.5 million confirmed deaths.[1] 
Among the catastrophe, the COVID-19 preventive vaccinations have been a ray of hope. The World Health Organization 
(WHO) approved Comirnaty (Pfizer/BioNTech) as the first COVID-19 vaccine for emergency use on 31 December 2020. 
The list has been updated with six more vaccines till now; Oxford-AstraZeneca, Janssen (Johnson & Johnson), 
AstraZeneca-SK Bio, Covishield, Moderna, and recently, Sinopharm.[2] Comirnaty (Pfizer/BioNTech) and Moderna are 
modified mRNA-based vaccines. Oxford-AstraZeneca and Janssen use a recombinant adenoviral vector encoding the 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein. The AstraZeneca-SK Bio and 
Covishield are basically the versions of Oxford-AstraZeneca that are manufactured in South Korea and India, 
respectively, using the same techniques. Sinopharm vaccine uses an inactivated SARS-COV-2 virus. Vaccine efficacy 
to prevent symptomatic COVID-19 disease ranges from 65 - 95% [3] and over 1.7 billion vaccine doses have so far 
been administered.[1]
Since the vaccines have been fast-tracked for emergency use, the short and long-term safety profile has been a point 
of concern. These concerns escalated when multiple cases of thromboembolism along with thrombocytopenia were 
initially reported in AstraZeneca (AZ) vaccine recipients in early March 2021, which led to a temporary suspension of 
the AZ vaccination in European countries for further investigation.[4] An initial study reported 11 patients (82% females) 
with thromboembolic complications after the AZ vaccine. The majority of them had cerebral venous thrombosis (CVT) 
(82%; n=9) followed by splanchnic vein and pulmonary thrombosis (n=3 each). Some patients experienced >1 
thrombotic event.[5] Besides AZ, Jannsen recipients also developed rare thrombosis and thrombocytopenia. Janssen 
vaccine was briefly suspended on 10 April 2021 when 6 persons out of 6.8 million doses of Janssen vaccine 
developed CVT along with thrombocytopenia. After two weeks, the U.S. Food and Drug Administration (FDA) resumed 
the Janssen use labeling the vaccine-induced thrombotic thrombocytopenia (VITT), also called thrombosis with 
thrombocytopenia syndrome (TTS), as its rare adverse effect. As of April 23, 2021, only 15 cases of VITT/TTS were 
reported after the Janssen vaccine. Interestingly, all of these cases occurred in young women with a median age of 37 
years and within two weeks post-vaccination.[6]
A binational population-based study from Denmark and Norway analyzed the rates of thrombosis within the 28-day 
period post-AZ vaccination (n= 281,264). They concluded a higher rate of venous thromboembolism corresponding 
to a standardized morbidity ratio (SMT) of 1.97 (95% CI, 1.50 – 2.54) and 11 excess venous thromboembolic events 
per 100,000 vaccinations as compared to the general population. A clear higher rate of CVT was, however, reported 
with an SMT of 20.25 (95% CI, 8.14 – 41.73) and 2.5 excess events per 100,000 vaccinations. No increase in 
arterial thromboembolic events was reported with SMT of 0.97 (95% CI, 0.77 – 1.20) but a higher SMT of 2.33 (95% 
CI; 1.01 – 4.59) for intracerebral hemorrhage was seen.[3]
CVT after COVID-19 vaccines is presumed to be due to immune response to platelet factor 4 (PF4). This is supported 
by the presence of platelet-activating antibodies as well as strong reactivity of post-vaccine CVT patients’ sera in 
anti-PF4/heparin enzyme immunoassay. The pathogenesis is similar to heparin-induced thrombocytopenia (HIT), which 
is a prothrombotic disorder and consumes platelets causing thrombocytopenia.[7] The only difference is that most of 
the persons with VITT have no previous history of heparin use and the immune-triggering factor is supposed to be 
something else, albeit still relatively unknown. In recent years, multiple triggers other than heparin have been 
recognized that may cause a prothrombotic disorder, similar to HIT. These triggers include various polyanionic 
compounds (e.g., pentosanpolysulfate), hypersulfated chondroitin sulfate, infections, or certain procedures, for 
instance, total knee arthroplasty.[8]
E D I T O R I A L
CVT, on other hand, is also reported in COVID-19 patients, presumably due to a hypercoagulable state.[9,10] A 
retrospective cohort study from the United States (US), available as a non-peer-reviewed preprint, reported a higher 
CVT incidence of 39.0 per million COVID-19 patients (n=513,284) as compared to 0.41 per million in general 
population and 4.1 per million who received vaccination (RR 6.36, P<0.001). Vaccine recipients in this study had an 
mRNA vaccine, either Pfizer-BioNTech or Moderna, since AstraZeneca is not available in the US. The authors concluded 
that the risk of CVT after COVID-19 is approximately 8-10 times higher than reported for the vaccines, and about 
100-fold higher than the general population.[11] An estimated risk of CVT after the AZ vaccine is reported to be 2.6 
cases per million people in UK over the 4-month period (62 CVT cases among the near 25 million people 
vaccinated).[12] With the number of reported post-vaccination CVT cases with AZ, the CVT incidence rate  of 2.6 
(compared to 4.1 with Pfizer and Moderna vaccines[11] seems an understatement. The other possibility is of 
observational (detection) bias. The level of attention given to the sporadic CVT cases in vaccine-recipients is many 
times higher than given to the routine CVT cases in daily practice, giving an impression of increased numbers.[12] 
Although for rare events and cross-sectional studies, a cause-and-effect relationship cannot be easily assessed, an 
increased CVT reporting in recipients of AZ and Janssen vaccines along with the almost total absence of cases after 
Pfizer, Moderna, or Sinopharm vaccines is something to look for. Additional findings of thrombocytopenia, which is not 
normally found in CVT patients, also hints towards a possible association. 
Recognition of VITT/TTS has certain important clinical and epidemiological implications. First, healthcare workers 
should be aware that the onset of thrombosis, particularly CVT, may occur up to two weeks post-vaccination for timely 
diagnosis and management. To date, this has only been reported with the AZ and Janssen vaccines. Second, HIT 
enzyme immunoassays may be used to investigate potential anti-PF4 antibody-associated VITT/TTS. Third, due to the 
lack of available data, the safety and efficacy of heparin in VITT/TTS is not known. Use of non-heparin anticoagulants 
(e.g. rivaroxaban, apixaban) is recommended. Intravenous immune globulin may also be used in severe cases. Fourth, 
the risk of CVT in COVID-19 patients is many folds higher than with vaccination, albeit the association with the later 
still need to be ascertained, and the vaccines are our main tools to control this deadly pandemic. Fifth, the main 
similarity between AZ and Janssen is the use of a recombinant adenoviral vector as a transport medium to deliver the 
genetic material of SARS-CoV-2 spike protein to human cells to trigger an immune response. The question of whether 
the rare occurrence of VITT/TTS is related to adenoviral vector is still elusive and needs further research. Data of other 
COVID-19 vector-vaccines pending WHO approval, for instance, Russian Sputnik V or Chinese CanSino vaccine, should 
be carefully analyzed for thromboembolic events and thrombocytopenia.
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